Vivos Therapeutics to Reschedule Second Quarter 2023 Financial Results Conference Call
August 14 2023 - 5:06PM
Vivos Therapeutics, Inc. (“Vivos” or the “Company”) (NASDAQ: VVOS),
a medical technology company focused on developing and
commercializing innovative diagnostic and treatment methods for
patients suffering from a variety of health conditions, many of
which are associated with breathing related sleep conditions
arising from certain dentofacial abnormalities, today announced it
will reschedule its conference call to review its financial results
for the second quarter ended June 30, 2023, previously scheduled
for today at 5:00 p.m. (Eastern Time). Further details for the
second quarter financial results conference call will be provided
in a subsequent announcement.
Vivos expects it will be unable to file its Form
10-Q for the quarter ended June 30, 2023 (the “Form 10-Q”) within
the prescribed time period. The Company and its independent
registered public accounting firm require additional time to review
certain disclosures related to the Company’s accounting for and
disclosures related to the Company’s Employee Retention Credit
previously received under Section 2301 of the Coronavirus Aid,
Relief, and Economic Security Act of 2020. The Company is working
diligently to complete its Form 10-Q for such period as soon as
possible and currently expects to file the Form 10-Q within the
five-day extension period provided under Rule 12b-25 of the
Securities Exchange Act of 1934, as amended.
About Vivos Therapeutics,
Inc.
Vivos Therapeutics, Inc. (NASDAQ: VVOS) is a
medical technology company focused on developing and
commercializing innovative diagnostic and treatment methods for
patients suffering from breathing and sleep issues arising from
certain dentofacial abnormalities such as mild-to-moderate
obstructive sleep apnea (OSA) and snoring in adults. The Vivos
Method represents the first clinically effective nonsurgical,
noninvasive, nonpharmaceutical and cost-effective solution for
treating mild to moderate OSA. It has proven effective in
approximately 40,000 patients treated worldwide by more than 1,800
trained dentists.
The Vivos Method includes the Vivos Complete
Airway Repositioning and/or Expansion (CARE) appliance therapy and
associated protocols that alter the size, shape and position of the
soft tissues that comprise a patient’s upper airway and/or palate.
The Vivos Method opens airway space and may significantly reduce
symptoms and conditions associated with mild-to-moderate OSA, such
as lowering Apnea Hypopnea Index scores. Vivos also markets and
distributes SleepImage diagnostic technology under its VivoScore
program for home sleep testing in adults and children. The Vivos
Integrated Practice (VIP) program offers dentists training and
other value-added services in connection with using The Vivos
Method.
For more information, visit
www.vivos.com.
Cautionary Note Regarding
Forward-Looking StatementsThis press release, the
conference call referred to herein, and statements of the Company’s
management made in connection therewith contain “forward-looking
statements” (as defined in Section 27A of the Securities Act of
1933, as amended, and Section 21E of the Securities Exchange Act of
1934, as amended) concerning future events, particularly with
respect to the public offering described herein. Words such as
“may”, “should”, “expects”, “projects”, “intends”, “plans”,
“believes”, “anticipates”, “hopes”, “estimates”, “goal” and
variations of such words and similar expressions are intended to
identify forward-looking statements. These statements involve
significant known and unknown risks and are based upon several
assumptions and estimates, which are inherently subject to
significant uncertainties and contingencies, many of which are
beyond Vivos’ control. Actual results (including, without
limitation, the results of Vivos’ sales, marketing and cost cutting
initiatives as described herein) may differ materially from those
expressed or implied by such forward-looking statements. Factors
that could cause actual results to differ materially include, but
are not limited to: (i) the risk that Vivos may be unable to
implement revenue, sales and marketing strategies that increase
revenues, (ii) risks associated with regulatory scrutiny of and
adverse publicity in the sleep apnea treatment sector; (iii) the
risk that Vivos may be unable to secure additional financings on
reasonable terms when needed, if at all and (iv) other risk factors
described in Vivos’ filings with the Securities and Exchange
Commission (“SEC”). Vivos’ filings can be obtained free of charge
on the SEC’s website at www.sec.gov. Except to the extent required
by law, Vivos expressly disclaims any obligations or undertaking to
release publicly any updates or revisions to any forward-looking
statements contained herein to reflect any change in Vivos’
expectations with respect thereto or any change in events,
conditions, or circumstances on which any statement is based.
Vivos Investor Relations
Contact:Julie GannonInvestor Relations
Officer720-442-8113jgannon@vivoslife.com
Vivos Therapeutics (NASDAQ:VVOS)
Historical Stock Chart
From Apr 2024 to May 2024
Vivos Therapeutics (NASDAQ:VVOS)
Historical Stock Chart
From May 2023 to May 2024